Effects of Botulinum Toxin A on Cytokine Synthesis in a Cell Culture Model of Cutaneous Scarring

Ohmann, Elisabeth

doi:10.1001/archfacial.2011.734

Cited by 20 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen (L. Chen et al, 2019) showed that BTA could reduce the proliferation and migration of fibroblasts through JNK pathway activation, and inhibit the protein expression levels of TGF-β, IL-6 and connective tissue growth factor (CTGF). In contrast, in a culture with dermal fibroblasts and microvascular endothelial cells, the above phenomenon was not observed (Haubner et al, 2012). Verapamil is also a controversial drug for scars.…”

Section: Synthetic Drugsmentioning

confidence: 89%

Therapeutic Strategies by Regulating Interleukin Family to Suppress Inflammation in Hypertrophic Scar and Keloid

Zhang

Zhao

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Hypertrophic scar (HS) and keloid are fibroproliferative disorders (FPDs) of the skin due to aberrant wound healing, which cause disfigured appearance, discomfort, dysfunction, psychological stress, and patient frustration. The unclear pathogenesis behind HS and keloid is partially responsible for the clinical treatment stagnancy. However, there are now increasing evidences suggesting that inflammation is the initiator of HS and keloid formation. Interleukins are known to participate in inflammatory and immune responses, and play a critical role in wound healing and scar formation. In this review, we summarize the function of related interleukins, and focus on their potentials as the therapeutic target for the treatment of HS and keloid.

show abstract

Section: Synthetic Drugsmentioning

confidence: 89%

Therapeutic Strategies by Regulating Interleukin Family to Suppress Inflammation in Hypertrophic Scar and Keloid

Zhang

Zhao

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…19 Furthermore, any concentration of BTXA seems to have no negative impact on normal skin tissue, confirming that BTXA targets only scar cell fibroblasts while leaving normal skin tissue unaffected. 20…”

Section: Mechanism Of Botulinum Toxin In the Treatment Of Scarsmentioning

confidence: 99%

Current Research of Botulinum Toxin Type A in Prevention and Treatment on Pathological Scars

Wang

Zhang

et al. 2023

Dermatol Surg

View full text Add to dashboard Cite

BACKGROUND Dermatologists have been looking for ways to improve wound healing and postoperative scar appearance. The safety and efficacy of botulinum toxin type A (BTXA) in the prevention and treatment on pathological scars have become the current research hotspot since it was approved by the US FDA in medical cosmetology in 2002. PURPOSE This article aims to provide an overview of the clinical research, limitations, and application prospects of BTXA in the prevention and treatment of traumatic or postoperative pathological scars, which can provide a reference and better understanding of relevant studies. METHODS The current research progress was summarized and discussed, with new problems and research ideas being proposed ranging from the molecular mechanism of BTXA in preventing and treating pathological scars to its clinical application via investigation and reference research. RESULTS BTXA is effective in relieving itching and pain associated with pathological scars, limiting scar hyperplasia along with preventing scar contracture, but the specific mechanism is still not clear. CONCLUSION Most of the clinicians have confirmed the clinical effectiveness of BTXA in the prevention and treatment of pathological scars, yet its mode of action and combination therapy need more research.

show abstract

“…Most authors have utilized fibroblasts that are derived from hypertrophic scars. Haubner et al, 34 investigated the effects of Botox on normal human skin fibroblasts and dermal micro-vascular endothelial cells. After incubating the cells with different concentrations of Botox, the toxin did not show any effect on the expression of cytokines or other growth factors (such as monocyte chemoattractant protein 2, fibroblast growth factors, macrophage colony-stimulating factor, and vascular endothelial growth factor).…”

Section: Botulinum Toxin In Wound Healing and Facial Scarringmentioning

confidence: 99%

Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair

Al‐Qattan

Alshanawani

Alshomer

2013

Annals of Saudi Medicine

View full text Add to dashboard Cite

Botulinum toxin is a neurotoxin that has been utilized to induce chemo-denervation of muscles. Cutaneous wounds represent a special situation in which the tensile forces applied by these muscles on wound edges might have deleterious effects on the healing process. The aim of this review was to investigate such an effect and to review other mechanisms this toxin might have on the healing process. We also reviewed the role of botulinum toxin in the management of hypertrophic scars and cleft lip repair.

show abstract

Effects of Botulinum Toxin A on Cytokine Synthesis in a Cell Culture Model of Cutaneous Scarring

Cited by 20 publications

References 24 publications

Therapeutic Strategies by Regulating Interleukin Family to Suppress Inflammation in Hypertrophic Scar and Keloid

Therapeutic Strategies by Regulating Interleukin Family to Suppress Inflammation in Hypertrophic Scar and Keloid

Current Research of Botulinum Toxin Type A in Prevention and Treatment on Pathological Scars

Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair

Contact Info

Product

Resources

About